课题基金 / 基金详情

Genetic Modifiers of Iron Status in Hemochromatosis HFE C282Y Homozygotes

Genetic Modifiers of Iron Status in Hemochromatosis HFE C282Y Homozygotes
血色病 HFE C282Y 纯合子铁状态的遗传修饰
批准号:
9084546
负责人:
Paul Clifford Adams
金额:
$73.81万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2019-06-30

项目摘要

项目成果

Paul Clifford Adams的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Approximately 1 million people in the United States are at risk for development of iron overload, attributable primarily to the genetic disorder known as hemochromatosis (HH). Once considered a rare disease, HH is now recognized as one of the most common autosomal recessive disorders, occurring in approximately 5 persons per 1,000 in populations of northern European descent. Most patients with hemochromatosis are homozygous for the C282Y mutation in the HFE gene. This inborn error of iron metabolism is characterized by excessive dietary iron absorption and progressive accumulation of iron in the body, typically reaching toxic levels by mid life. The overall goal of this research is to answer te question, "What role do genetic modifiers play in determining iron accumulation in persons homozygous for the HFE C282Y genotype?" With assistance from a R24 seeding grant, we have established an international collaborative research team, developed and validated a phenotyping protocol and performed preliminary studies. This full R24 project will utilize current capabilities of exome sequencing followed by targeted sequencing of iron-related genome regions and single nucleotide variants to identify rare and common causal variants associated with severe or mild iron expression in hemochromatosis patients. An efficient selective genotyping study design will be used for which three comparison groups have been identified, HFE C282Y homozygotes with normal or minimally elevated iron stores (low expression) at the time of first diagnosis, HFE C282Y homozygotes with markedly increased iron stores (high expression) at diagnosis, and a third group of non-hemochromatosis subjects who have normal iron stores and no HFE mutations. A follow-up validation study will be preformed and a model will be developed for predicting risk of high expression. This research will provide insight into possible genetic contributions to susceptibility or resistance to iron overload, help to understand the significant variation in iron loading in different individuals with this disorder and the relationship to clinical manifestations, and ultimately lead to development of innovative prevention and treatment strategies tailored to the individual. PHS 398/2590 (Rev. 06/09) Page Continuation Format Page
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic Modifiers of Iron Status in Hemochromatosis HFE C282Y Homozygotes
  • 批准号:
    8771261
  • 项目类别:
  • 资助金额:
    $59.52万
  • 财政年份:
    2014
  • 负责人:
    Paul Clifford Adams
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: